ACOBIOM

Belkins
Acobiom is specialized in the identification of new Biomarkers and in the development of innovative Diagnostics in Translational Research and Precision Medicine. The company provides also customized services in genomics, transcriptomics, bioinformatics and biostatistics (data science), thanks to its technology platform and its scientific expertise.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

RESEARCH

TURTLETREE LAUNCHES NEW RESEARCH AND DEVELOPMENT FACILITY IN GREATER SACRAMENTO

TurtleTree | October 04, 2021

news image

TurtleTree has officially opened its new R&D facility in California's state capital. Located in West Sacramento, this 24,000-square-foot building will house a world-class research hub showcasing the company's extensive array of innovations and cell-based technologies. Representing a milestone in TurtleTree's US-based expansion plans, the research facility will spur the development of precision fermentation technology currently used to produce valuable milk in...

Read More

REVITOPE, JUNSHI BIOSCIENCES ENTER INTO RESEARCH COLLABORATION TO DEVELOP FIRST-IN-CLASS DUAL-ANTIGEN TARGETING CANCER THERAPIES

Revitope Oncology | July 14, 2020

news image

Revitope Oncology Inc ("Revitope Oncology")., a biotechnology company advancing a new class of precision cancer immunotherapies, its wholly-owned subsidiary Revitope Limited (Revitope Limited, together with Revitope Oncology, "Revitope") and Junshi Biosciences (1877.HK, 688180.SH), a leading innovation–driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the companies have entered into a stra...

Read More

RESEARCH

PHARMABCINE TO PRESENT UPDATED INTERIM DATA FROM THE ONGOING PHASE IB TRIAL OF OLINVACIMAB AND PEMBROLIZUMAB COMBINATION THERAPY

PharmAbcine | December 08, 2020

news image

PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020.
Read More

MEDTECH

MEDTRONIC EXPANDS MINIMALLY INVASIVE SPINE SURGERY ECOSYSTEM WITH NEXT-GENERATION SPINAL TECHNOLOGIES

Medtronic plc | October 01, 2021

news image

Medtronic plc, the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients. New additions to the Medtronic MIS+ portfolio include: Catalyft™ PL and PL40, the first releases in the new Catalyft™ Expandable Interbody System. Catalyft™ ...

Read More

RESEARCH

TurtleTree | October 04, 2021

news image

TURTLETREE LAUNCHES NEW RESEARCH AND DEVELOPMENT FACILITY IN GREATER SACRAMENTO

TurtleTree has officially opened its new R&D facility in California's state capital. Located in West Sacramento, this 24,000-square-foot building will house a world-class research hub showcasing the company's extensive array of innovations and cell-based technologies. Representing a milestone in TurtleTree's US-based expansion plans, the research facility will spur the development of precision fermentation technology currently used to produce valuable milk in...

Read More

Revitope Oncology | July 14, 2020

news image

REVITOPE, JUNSHI BIOSCIENCES ENTER INTO RESEARCH COLLABORATION TO DEVELOP FIRST-IN-CLASS DUAL-ANTIGEN TARGETING CANCER THERAPIES

Revitope Oncology Inc ("Revitope Oncology")., a biotechnology company advancing a new class of precision cancer immunotherapies, its wholly-owned subsidiary Revitope Limited (Revitope Limited, together with Revitope Oncology, "Revitope") and Junshi Biosciences (1877.HK, 688180.SH), a leading innovation–driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the companies have entered into a stra...

Read More

RESEARCH

PharmAbcine | December 08, 2020

news image

PHARMABCINE TO PRESENT UPDATED INTERIM DATA FROM THE ONGOING PHASE IB TRIAL OF OLINVACIMAB AND PEMBROLIZUMAB COMBINATION THERAPY

PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020.
Read More

MEDTECH

Medtronic plc | October 01, 2021

news image

MEDTRONIC EXPANDS MINIMALLY INVASIVE SPINE SURGERY ECOSYSTEM WITH NEXT-GENERATION SPINAL TECHNOLOGIES

Medtronic plc, the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients. New additions to the Medtronic MIS+ portfolio include: Catalyft™ PL and PL40, the first releases in the new Catalyft™ Expandable Interbody System. Catalyft™ ...

Read More